Business Case Study: Mylan

The company has been engaged in a dispute over a long-standing litigation with W Inc. The dispute involves a specific patent infringement matter. In May 2007, W Inc. filed a claim against the company for patent infringement and management determined that a loss was probable and estimated it would be between $15 million and $20 million, with $17 million being the most likely amount of loss within the estimated range (December 31, 2007). In September 2009, a jury trial took place for the litigation involving the company and W Inc. A verdict for the trial was reached; a judgment was ordered that

We didn’t find that any of the board members were employed with the company in the past and interlocking directorship is not found neither. There is three female board members which is very good number taking the highest number of females in the board

This review will address several issues associated with the legal, business, and ethics related to the case. First, it will address the legality of the case by reviewing the definition and analysis of the Uniform Commercial Code (UCC), Article 2. Next, this review will analyze the business effects of the case as they relate to the monetary bottom line and Stylarama’s attempt to protect his profits. Finally, it will highlight

Because the Board of Directors only meets four times a year, the day-to-day operations are managed by a Chief Executive Officer. The CEO has appointed five Chiefs as his

1. Member Board of Directors – Each Director serves for three-year terms and may be reelected. There are 21 members currently serving on the Board.

There are many concepts from our course related to this case. The effectiveness of any law depends on how the courts interpret it and on the vigor of government enforcement (McConnell, et al., 2012). While the jury found that Marshfield clinic and Security had monopoly power, that they engaged in anticompetitive conduct to obtain or maintain that power, and found that Marshfield had illegally entered into agreements with competitors or potential competitors to allocate customers, allocate territories, allocate markets, and to fix fees or prices, the judge subsequently found much of the jury’s decision not reflective of the evidence and over-turned much of the antitrust violations. If this made Marshfield price makers then they could only be characterized as, at the very least, a monopolistic competition all the way up to a monopoly. If a large fraction of the population of Wisconsin could not find “independent” physicians to offer a competitive HMO product, then this clearly would put them as an oligopoly or even monopoly.

“In my opinion, the Case would be improved by including the following summary” An American agriculture of the nineteenth century Cyrus McCormick, invented a company that produced farming equipment called McCormick Harvesting Machine Company. In 1902 his son Cyrus McCormick II merged the company with three competitors renaming it the International Harvester Company. By the late 1980’s the company had moved from producing farming equipment to manufacturing automotive products, trucks, and school buses. In the late 1980’s International Harvester company was renamed Navistar International Corporation. Over the years NIC changed and one of the most dramatic changes was the relationship with its longtime auditor Deloitte. (Knapp, 2015)

Facts of the Case- In March 2010, there came about multiple lawsuits that were merged into one case shortly after Congress passed the Patient Protection and Affordable Care Act (ACA) or Obamacare (National Federation of Independent Business v. Sebelius). With the passing of this act it required U.S. citizen who did not already have health care through Medicaid, Medicare, corporate, or any government-sponsored source to get health care. Citizens who did not have any of the mentioned healthcare sources would be forced into buying into the federally funded healthcare. If they did not buy into the healthcare, there would be a strict penalty

1) Evaluate HTC’s performance as described in the case. What are its competitive assets and liabilities?

The following table sets forth certain information with respect to the executive officers and directors as of September 1, 2009:

On March 19 of the year 2003, Securities and Exchange Commission brought the trading of HealthSouth to an end on the New York stock exchange, charging the company for inflating its earnings by more than 10 percent and overstated its profits by more than $2.5 billion between 1999 and 2002. HealthSouth’s trading reached to $30.81 in the year 1998, but ever since the trading of the company has been put to an end it reached to $3.91 per share. One week later, Owens pleaded guilty to changing and editing the company’s financial statements.

The Board of the Company consists of 11 (eleven) Independent Directors and 2 (two) Inside Directors. They have expertise in the areas of business, finance, law, audit and public companies.

On August 29, 2016, Mylan released a written statement to the press about their plan to develop a generic EpiPen after the outrage over the increased price of their brand name EpiPen. It begins:

Joshua Kennon (2007), stated that “The board of directors is the highest governing authority within the management structure at any publicly traded company and is usually made up of the directors who are elected for a specific number of years by the shareholders”. According to Wikipedia,” A board of directors is a body of elected or appointed members who jointly oversee the activities of a company or organization”.

On April 21, 2015, Teva, the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide which headquartered in Petah Tikva, Israel, officially announced a proposal to acquire Mylan, the second largest generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, for＄82.00 per Mylan share approximately 50% in Cash and 50% in stock.